{4-[8-(3,5-difluoro-4-morpholin-4-ylmethyl-phenyl)-quinoxalin-2-yl]-1-methyl-1H-pyrrol-2-yl}-(4-methyl-piperazin-1-yl)-methanone | 1092500-61-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: {4-[8-(3,5-difluoro-4-morpholin-4-ylmethyl-phenyl)-quinoxalin-2-yl]-1-methyl-1H-pyrrol-2-yl}-(4-methyl-piperazin-1-yl)-methanone
• 英文别名: [4-[8-[3,5-Difluoro-4-(morpholin-4-ylmethyl)phenyl]quinoxalin-2-yl]-1-methylpyrrol-2-yl]-(4-methylpiperazin-1-yl)methanone
• CAS: 1092500-61-2
• 化学式: C₃₀H₃₂F₂N₆O₂
• 分子量: 546.62
• InChiKey: IDHRWMYQQIQTFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  40
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  66.7
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors
  申请人：Gerspacher Marc

  公开号：US20100168062A1

  公开（公告）日：2010-07-01

  The present invention relates to quinoxaline compound of the formula (I): wherein R 1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R 7 ; R 2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R 8 ; R 3 , R 4 , R 5 and R 8 are each independently hydrogen or R 9 ; and R 7 , R 8 and R 9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.

  本发明涉及式（I）的喹喔啉化合物：其中R1是碳环或杂环，其中任一可以用1、2、3、4或5个R7取代; R2是碳环或杂环，其中任一可以用1、2、3、4或5个R8取代; R3、R4、R5和R8各自独立地是氢或R9; 而R7、R8和R9各自独立地选自有机和无机取代基，在治疗疾病中的应用，特别是由Janus激酶的酪氨酸激酶活性介导的疾病，包括JAK-2和JAK-3激酶。
• QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES
  申请人：Novartis AG

  公开号：EP2155201B1

  公开（公告）日：2012-08-01
• US8193189B2
  申请人：——

  公开号：US8193189B2

  公开（公告）日：2012-06-05